[Federal Register Volume 79, Number 192 (Friday, October 3, 2014)]
[Notices]
[Pages 59776-59779]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-23596]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-D-0360]
Framework for Regulatory Oversight of Laboratory Developed Tests;
Draft Guidance for Industry, Food and Drug Administration Staff, and
Clinical Laboratories; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of the draft guidance entitled ``Framework for Regulatory
Oversight of Laboratory Developed Tests (LDTs).'' This document
describes a risk-based framework for addressing the regulatory
oversight of a subset of in vitro diagnostic devices (IVDs) referred to
as laboratory developed tests (LDTs), which are intended for clinical
use and designed, manufactured and used within a single laboratory.
This document describes FDA's priorities for enforcing pre- and post-
market requirements for LDTs, and the process by which FDA intends to
phase in enforcement of FDA regulatory requirements for LDTs over time.
This draft guidance is not final, nor is it in effect at this time.
DATES: Although you can comment on any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency considers your comment on this
draft guidance before it begins work on the final version of the
guidance, submit either electronic or written comments on the draft
guidance by February 2, 2015.
ADDRESSES: An electronic copy of the guidance document is available for
download from the Internet. See the SUPPLEMENTARY INFORMATION section
for information on electronic access to the guidance. Submit written
requests for single hard copies of the draft guidance document entitled
``Framework for Regulatory Oversight of Laboratory Developed Tests
(LDTs)'' to the Office of the Center Director, Guidance and Policy
Development, Center for Devices and Radiological Health (CDRH), Food
and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5431,
Silver Spring, MD 20993-0002, or the Office of Communication, Outreach,
and Development, Center for Biologics Evaluation and Research (CBER),
Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm.
3128, Silver Spring, MD 20993-0002. Send one self-addressed adhesive
label to assist that office in processing your request. The guidance
may also be obtained by mail by calling CBER at 1-800-835-4709 or 240-
402-7800.
Submit electronic comments on the draft guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852. Identify comments with the docket number
found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: [email protected]; or Katherine
Serrano, Center for Devices and Radiological Health, Food and Drug
Administration, Bldg. 66, Rm. 5646, 10903 New Hampshire Ave., Silver
Spring, MD 20993-0002, 240-402-4217; or Stephen Ripley, Center for
Biologics Evaluation and Research Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002,
240-402-7911.
SUPPLEMENTARY INFORMATION:
I. Background
In 1976, Congress enacted the Medical Device Amendments (MDA),
which amended the Federal Food, Drug, and Cosmetic Act (the FD&C Act)
to create a comprehensive system for the regulation of medical devices
intended for use in humans. At that time, the definition of a device
was amended to make explicit that it encompassed in vitro diagnostic
devices (IVDs): ``The term `device'. . . means an instrument,
apparatus, implement, machine, contrivance, implant, in vitro reagent,
or
[[Page 59777]]
other similar or related article . . .'' (section 201(h) of the FD&C
Act (21 U.S.C. 321(h)). The definition of device applies equally to
IVDs manufactured by conventional device manufacturers and those
manufactured by laboratories. An IVD, therefore, meets the device
definition irrespective of where and by whom it is manufactured.
Since the implementation of the MDA of 1976, FDA has exercised
enforcement discretion so that the Agency has generally not enforced
applicable provisions under the FD&C Act and FDA regulations with
respect to laboratory developed tests (LDTs), a subset of in vitro
diagnostic devices that are intended for clinical use and designed,
manufactured, and used within a single laboratory.
In 1976, LDTs were mostly manufactured in small volumes by local
laboratories. Many laboratories manufactured LDTs that were similar to
well-characterized, standard diagnostic devices, as well as other LDTs
that were intended for use in diagnosing rare diseases or for other
uses to meet the needs of a local patient population. LDTs at the time
tended to rely on the manual techniques used by laboratory personnel.
LDTs were typically used and interpreted directly by physicians and
pathologists working within a single institution that was responsible
for the patient. In addition, historically, LDTs were manufactured
using components that were legally marketed for clinical use (i.e.,
general purpose reagents, immunohistochemical stains, and other
components marketed in compliance with FDA regulatory requirements).
Although some laboratories today still manufacture LDTs in this
``traditional'' manner, the landscape for laboratory testing in
general, and LDTs along with it, has changed dramatically since 1976.
Today, LDTs are often used in laboratories that are independent of the
healthcare delivery entity. Additionally, LDTs are frequently
manufactured with components and instruments that are not legally
marketed for clinical use and also rely more heavily on complex, high-
tech instrumentation and software to generate results and clinical
interpretations. Moreover, technological advances have increased the
use of diagnostic devices in guiding critical clinical management
decisions for high-risk diseases and conditions, particularly in the
context of personalized medicine.
Business models for laboratories have also changed since 1976. With
the advent of overnight shipping and electronic delivery of information
(e.g., device results), a single laboratory can now easily provide
device results nationally and internationally. Today, many new LDT
manufacturers are large corporations that nationally market a limited
number of complex, high-risk devices, in contrast to 1976 when hospital
or public health laboratories used a wide range of devices that were
generally either well characterized and similar to standard devices;
used to diagnose rare diseases; or designed specifically to meet the
needs of their local patients. Together, these changes have resulted in
a significant shift in the types of LDTs developed, the business model
for developing them, and the potential risks they pose to patients.
Because of changes in the complexity and use of LDTs and the
associated increased risks, as described earlier, FDA believes the
policy of general enforcement discretion towards LDTs is no longer
appropriate. To initiate this step toward greater oversight, FDA held a
two-day public meeting on July 19 and 20, 2010, to provide a forum for
stakeholders to discuss issues and concerns surrounding greater
oversight of LDTs. Comments submitted to the public docket for the July
public meeting have been addressed, as appropriate, in the draft
guidance document.
Once finalized and implemented, this guidance document is intended
to provide a risk-based oversight framework that will assure that
devices used in the provision of health care, whether developed by a
laboratory or a conventional IVD manufacturer, comply with the
appropriate levels of regulatory controls needed to assure that they
are safe and effective. Under the framework outlined in this guidance
document, FDA intends to continue to exercise enforcement discretion
for all applicable regulatory requirements for LDTs used solely for
forensic (law enforcement) purposes as well as certain LDTs for
transplantation when used in certified, high-complexity
histocompatibility laboratories. Additionally, FDA intends to exercise
enforcement discretion for applicable premarket review requirements and
quality systems requirements, but enforce other applicable regulatory
requirements, including registration and listing (with the option to
provide notification instead) and adverse event reporting, for low risk
LDTs (class I devices), LDTs for rare diseases, Traditional LDTs and
LDTs for Unmet Needs, as described in the draft guidance document. For
other high and moderate risk LDTs, FDA intends to enforce applicable
regulatory requirements, including registration and listing (with the
option to provide notification instead) and adverse event reporting,
and phase in enforcement of premarket and quality system requirements
in a risk-based manner.
On July 31, 2014, as required by Section 1143 of the Food and Drug
Administration Safety and Innovation Act, FDA provided notification to
Congress of its intent to issue this draft guidance and the
accompanying draft guidance entitled ``FDA Notification and Medical
Device Reporting for Laboratory Developed Test (LDTs)'' (the
availability of the accompanying draft guidance is announced elsewhere
in this issue of the Federal Register). The anticipated details of
these draft guidance documents were included in the notification to
Congress.
Although FDA was not accepting formal comments on its notification
to Congress, the Agency has received informal comments and questions
regarding the anticipated details of this draft guidance provided in
the notification to Congress. To give everyone an opportunity to
provide formal comments on the anticipated details as part of the
administrative record, the details of the draft guidance are identical
to that which were included in FDA's July 31, 2014, notification to
Congress with the exception of the following technical amendments: The
definition of companion diagnostic has been updated for consistency
with the final guidance on ``In Vitro Companion Diagnostic Devices''
issued on August 6, 2014, and the ``Traditional LDT'' factor regarding
whether the LDT is comprised only of components and instruments that
are legally marketed has been clarified to more accurately reflect
FDA's intent of considering whether the LDT is comprised of only
components and instruments that are legally marketed for clinical use.
To provide greater transparency on certain questions and issues
that have been raised and to allow for broad public input, in addition
to welcoming comments on all aspects of this draft guidance, FDA seeks
feedback on the following specific issues:
Traditional LDTs: In Section D.5.(a) of the draft
guidance, FDA has proposed continued enforcement discretion for
premarket review and quality system requirements for a category of LDTs
called ``Traditional LDTs'' based on whether the device is: (1) an LDT
(designed, manufactured and used within a single laboratory); (2)
manufactured and used by a health care facility laboratory (such as one
located in a hospital or clinic) for a patient that is being diagnosed
and/or treated at that same health care facility or within the
facility's healthcare system; (3)
[[Page 59778]]
comprised only of components and instruments that are legally marketed
for clinical use; and (4) interpreted by qualified laboratory
professionals without the use of automated instrumentation or software
for interpretation. FDA believes that these factors appropriately
mitigate risks associated with Traditional LDTs being used on patients
so that continued enforcement discretion with respect to premarket
review and quality system requirements is appropriate. However, FDA is
seeking public feedback as to whether the following three factors may
be sufficient to appropriately mitigate risk for this category of tests
and whether they may also be sufficient to support continued
enforcement discretion in full (i.e., for all regulatory requirements
rather than just for premarket review and quality system requirements):
(1) the test is an LDT (designed, manufactured and used within a single
laboratory); (2) the test makes use of only components and instruments
that are legally marketed for clinical use, which have a number of
regulatory controls in place, including reporting of adverse events;
and (3) the test is interpreted by laboratory professionals who are
appropriately qualified and trained as required by the Clinical
Laboratory Improvement Amendments regulations (e.g., 42 CFR 493.1449),
without the use of automated instrumentation or software for
interpretation.
LDTs Used for Rare Diseases: In Section D.5.(a) of the
draft guidance, FDA has proposed continued enforcement discretion for
premarket review and quality system requirements for LDTs used for rare
diseases, which are those tests that meet the definition of LDT in the
guidance (designed, manufactured and used within a single laboratory)
and meet the definition of a Humanitarian Use Device (HUD) under 21 CFR
814.102(a)(5). With these factors, FDA has attempted to balance the
need to mitigate the risks associated with these tests with their
potential benefit for patients. FDA invites stakeholders to provide
feedback on the suitability of these factors for LDTs for rare
diseases. Further, FDA is seeking feedback on whether a factor other
than the HUD definition should be considered, such as a factor based on
the number of tests for a rare disease or condition that would likely
(based on the prevalence of the condition) be conducted annually in the
United States, and if so what the annual number of tests should be for
the purpose of defining an LDT as an LDT for a rare disease. FDA also
seeks feedback on whether enforcement discretion should be limited to
tests that are designed, manufactured and used within a single
laboratory.
Healthcare System: In Section D.5. of the draft guidance,
for the categories of tests called ``Traditional LDTs'' and ``LDTs for
Unmet Needs,'' FDA has identified factors it intends to consider in
continuing to exercise enforcement discretion for premarket review and
quality system requirements. One such factor is whether the LDT is both
manufactured and used by a healthcare facility laboratory (such as one
located in a hospital or clinic) for a patient that is being diagnosed
and/or treated at that same healthcare facility or within that
facility's healthcare system. To further clarify this factor, the
guidance document explains that ``healthcare system'' refers to a
collection of hospitals that are owned and operated by the same entity
and that share access to patient care information for their patients,
such as, but not limited to, drug order information, treatment and
diagnosis information, and patient outcomes. While FDA invites feedback
on all factors described in Section D.5. of the draft guidance, FDA
specifically requests feedback on whether enforcement discretion should
be limited, as proposed, to those LDTs that are both manufactured and
used by a healthcare facility laboratory. FDA also invites the public
to provide feedback to the Agency on which types of facilities would or
would not be considered within a healthcare system, or to offer an
alternative description of healthcare system for Agency consideration.
Quality System (QS) Phase-in: In Section D.6. of the draft
guidance, FDA has proposed to continue to exercise enforcement
discretion with respect to QS regulation requirements, codified in 21
CFR Part 820, until a manufacturer of a given LDT submits a Premarket
Approval (PMA) or FDA issues a 510(k) clearance order for the LDT.
Under this enforcement policy, the clinical laboratory manufacturing
and using the LDT will be responsible for having a quality system in
place that meets the minimum requirements codified in 21 CFR Part 820,
either at the time of PMA submission (the facility that makes the
device must pass an inspection as a condition of PMA approval as a
matter of law (21 CFR 814.45(a)(3)), or prior to market launch for
cleared devices, as applicable. FDA invites feedback on the timeframe
for phase-in enforcement of QS regulation requirements. Specifically,
FDA is considering whether those LDTs in the highest-risk category of
devices (described in section D.5.(c) of the draft guidance), which FDA
intends to generally enforce premarket review requirements 12 months
following publication of the final Framework guidance, should remain
under enforcement discretion for the design control requirements (21
CFR 820.30(a-h) and (j)) of the QS regulation for up to 24 months after
publication of the final guidance.
Notification: FDA notes that some laboratory networks
(i.e., more than one laboratory under the control of the same parent
entity) offer the same test in multiple laboratories throughout their
network. Although devices in this scenario do not meet FDA's definition
of an LDT (i.e., they are not designed, manufactured and used within a
single laboratory), FDA would like feedback on whether a single
notification from the laboratory network for that test is sufficient,
provided that the laboratory network indicates in the notification to
FDA that the test is offered at multiple sites. In addition, FDA seeks
comment on whether there are certain types of LDTs for which the Agency
should neither enforce requirements for registration and listing nor
request notification in lieu of registration and listing.
FDA understands that members of the public may want more
clarity around specific issues; such as how laboratory sponsors could
interpret what elements make up a medical device, what might constitute
the label or labeling for their device, whether or not unique device
identifier requirements apply to LDTs, and how laboratory-physician
communication about a test and its result would be viewed by FDA, among
others. We invite public comment on these issues and any other issues
or questions that should be addressed in the guidance, including how
that issue or question should be addressed.
Additionally, FDA intends to hold a public webinar in late October,
2014 to summarize the proposed oversight framework and answer
clarification questions from stakeholders. The webinar will not require
registration and will be announced at least one week in advance on
FDA's Web site. It will be recorded and made available on FDA's Web
site shortly thereafter.
II. Significance of Guidance
This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the Agency's current thinking on oversight of
laboratory developed tests. It does not create or confer any rights for
or on any person and does not operate to bind FDA or the public. An
[[Page 59779]]
alternative approach may be used if such approach satisfies the
requirements of the applicable statute and regulations.
III. Electronic Access
Persons interested in obtaining a copy of the draft guidance may do
so by downloading an electronic copy from the Internet. A search
capability for all CDRH guidance documents is available at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. Guidance documents are also available at
http://www.regulations.gov or the CBER Internet at http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm.
Persons unable to download an electronic copy of ``Framework for
Regulatory Oversight of Laboratory Developed Tests (LDTs)'' may send an
email request to [email protected] to receive an electronic
copy of the document. Please use the document number 1739 to identify
the guidance you are requesting.
IV. Paperwork Reduction Act of 1995
This draft guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in 21 CFR part 807 Subpart E have been
approved under OMB control number 0910-0120; the collections of
information in 21 CFR part 807 Subpart B and C have been approved under
OMB control number 0910-0625; the collections of information in 21 CFR
part 601 have been approved under OMB control number 0910-0338; the
collections of information in 21 CFR part 814, subparts B and E, have
been approved under OMB control number 0910-0231; the collections of
information in 21 CFR part 814, subpart H, have been approved under OMB
control number 0910-0332; the collections of information in 21 CFR part
820 have been approved under OMB control number 0910-0073; the
collections of information in 21 CFR part 812 have been approved under
OMB control number 0910-0078; the collections of information in 21 CFR
part 806 have been approved under OMB control number 0910-0359; the
collections of information in 21 CFR 801 and 21 CFR 809.10 have been
approved under OMB control number 0910-0485; and the collections of
information in 21 CFR part 803 have been approved under OMB control
numbers 0910-0291 and 0910-0437.
V. Comments
Interested persons may submit either electronic comments regarding
this document to http://www.regulations.gov or written comments to the
Division of Dockets Management (see ADDRESSES). It is only necessary to
send one set of comments. Identify comments with the docket number
found in brackets in the heading of this document. Received comments
may be seen in the Division of Dockets Management between 9 a.m. and 4
p.m., Monday through Friday, and will be posted to the docket at http://www.regulations.gov.
Comments will also be accepted at a public meeting, which will be
held prior to finalizing this draft guidance. A 2-day meeting is
tentatively scheduled for early January, 2015 and will be announced
separately in the Federal Register.
Dated: September 30, 2014.
Peter Lurie,
Associate Commissioner for Policy and Planning.
[FR Doc. 2014-23596 Filed 9-30-14; 11:15 am]
BILLING CODE 4164-01-P